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Background: Several plasma volume expander alternatives exist to enhance intravascular volume status in patients
undergoing surgery. The optimal intravascular volume expander in the perioperative setting is currently unknown.
Low molecular weight hetastarch, Voluven® (130/0.4), may have a better safety profile than high molecular weight
hetastarch, Hextend® (450/0.7). We examined the clinical and cost outcomes of converting from Hextend® to
Voluven® in a large tertiary medical center.
Methods: Using a large electronic database, we retrospectively compared two different time periods (2009 and
2010) where the availability of semisynthetic colloids changed. Perioperative and postoperative outcomes including
the use of red blood cells (RBC), platelets and coagulation factors, length of stay in the postoperative acute care
unit (PACU), intensive care unit and hospital, as well as 30-day and 1-year mortality were compared. In addition,
direct acquisition costs of all intraoperative and PACU colloids and crystalloid use were determined.
Results: A total of 4,888 adult subjects were compared of which 1,878 received Hextend® (pre-conversion) and
2,759 received Voluven® (post-conversion) during two separate 7-month periods within 1 year apart, with the
remainder receiving Plasmanate. The patients were similar in terms of patient demographics, preoperative
comorbidities, ASA status, emergency surgery, types of surgery, intraoperative, and PACU times. In unadjusted outcomes,
patients in the Hextend® group received more lactated Ringer’s than in the Voluven® group (2,220 + 1,312 vs.
1,946 ± 1,097 ml; P < 0.0001). The use of albumin (Plasmanate) was reduced from 10.5% of patients to 1.1% when
Voluven® was substituted for Hextend®. Unadjusted outcomes were similar in each group including hospital LOS,
percent change from baseline creatinine and receipt of intraoperative and PACU blood product administration.
However, overall unadjusted total fluid costs were greater in the Voluven® compared to Hextend® group ($116.7
compared to $59.3; P < 0.001).
Conclusions: Conversion from Hextend® to Voluven® in the perioperative period resulted in decreased albumin
use and was not associated with changes in clinical outcomes and short- and long-term mortality. The conversion
was associated with decreases in crystalloid use and an increase in colloid use and hence IV fluid acquisition costs
in the Voluven® group.
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Both human and semisynthetic colloids have been suc-
cessfully used to increase intravascular volume in the
perioperative period [1-4]. However, recent trials of vol-
ume replacement in the intensive care unit (ICU) have
questioned the safety and efficacy of both human and
synthetic colloids with one trial suggesting no benefit of
albumin over saline for resuscitation and others suggest-
ing harm with the use of semisynthetic colloids in this
patient population [5-8]. The issue of safety has not been
directly resolved in the perioperative setting. And, in
many institutions, semisynthetic colloids are still avail-
able for use in patients undergoing surgical procedures
where a benefit in decreased costs associated with intra-
operative volume replacement may exist.
One of these semisynthetic products, Voluven®, was
recently introduced into the US market. It has a lower
molecular weight (150 kD) and molar substitution (0.4)
and therefore has a theoretical lower plasma accumula-
tion and tissue storage [9,10]. Previous investigations
of Voluven® suggest less impact on factor VIII and Von
Willebrand factor concentrations with a sustained
plasma volume expansion effect resulting in less disturb-
ance of coagulation with subsequent reduced blood loss
and blood transfusion when compared to older larger mo-
lecular weight (MW) hydroxyethyl starch (HES) solutions
[11,12]. In addition, up to 50 ml/kg of Voluven® can be
given (about 3,500 ml in a 70-kg adult) compared to a
maximum of 1,500 ml (20 ml/kg) of high MW hydro-
xyethyl starch to adult patients [13,14]. Therefore, Volu-
ven® has the potential to reduce the need for other more
costly plasma volume expanders such as 5% albumin as
well as the need for blood transfusion. However, because
of recent recommendations against the use of these prod-
ucts in ICU patients by regulatory agencies, hospitals have
to evaluate the rationale for maintaining their availability
for use in the perioperative period.
Additionally, anesthesiologists in the US are limited to
using isotonic crystalloids and human albumin-based
products (albumin or Plasmanate) in patients requiring
intravascular volume expansion. Because of these insti-
tutional shifts of colloid types, hospital formulary costs
will change. Currently, there is paucity of data that have
examined the impact to hospital costs related to the use
of different intravascular volume expanders. Therefore,
we investigated two different periods evaluating the clin-
ical and direct acquisition cost impact of converting
from Hextend® to Voluven® in a large tertiary medical
center. By comparing cases in which some colloid was
given during two different periods, we sought to deter-
mine what differences in overall perioperative volume
use, overall fluid costs, and certain perioperative out-
comes might be associated with the use of the two dif-
ferent colloids.Methods
We conducted a retrospective comparison of two differ-
ent time periods at a large academic medical center,
Duke University Medical Center (DUMC). In March
2010, DUMC converted from Hextend® (hetastarch 6%,
MW 670 kD, in balanced electrolyte solution) to Voluven®
(hydroxyethyl tetrastarch 6% in sodium chloride 0.9%) as
the semisynthetic colloid for use in the perioperative
period. After Duke University Medical Center Institutional
Review Board approval, de-identified data was obtained
from an electronic anesthesia database which consists of
physiologic and treatment characteristics used for peri-
operative care of the patient. Because de-identified clinical
data was used, this study was determined to be exempt
from patient consent. Two separate 7-month periods were
investigated from 1 June 2009 to 30 December 2009
(Hextend®) and 1 June 2010 to 30 December 2010
(Voluven®). Anesthesia and surgical practice was other-
wise similar in these two time periods; however, overall
surgical volume increased due to increased operating
room capacity in 2010. We avoided the 3-month inter-
val before and after the conversion to ensure a period
of stability in practice. Pre- and postoperative data
were obtained by procedure ICD-9 codes, and our local
institutional data warehouse known as the Decision
Support Repositories was then linked to perioperative
anesthesia records. Follow-up closed for both periods
on 31 December 2012. All sequential cases greater
than 18 years old, who received Hextend®, Voluven®, or
albumin (Plasmanate®), were examined for inclusion.
Cases in which <500 ml of Hextend® or Voluven® were
recorded were not included in the analysis.
Patient demographics including gender, age, surgical
comorbidities, type of surgery, duration of surgery, and
type of anesthesia were obtained. Patient outcomes were
compared between HES periods including volume of all
crystalloids and colloids administered in the intraopera-
tive and post-anesthesia care unit (PACU), the use of red
blood cells (RBC) and platelets and coagulation factors.
The length of stay in the PACU, hospital length of stay,
intensive care unit length of stay, and 30-day and 1-year
mortality were also compared. Fluid costs were calcu-
lated using the Red book acquisition costs of each prod-
uct multiplied by the number of whole or partial units
received intraoperatively or in the PACU. For 2013,
these costs were Hextend® (500 ml) $37.80, Voluven®
(500 ml) $61.06, Plasmanate (250 ml) $41.00, lactated
Ringer’s (1,000 ml) $2.04, and 0.9% normal saline
(1,000 ml) $2.65.
Statistical analysis
Descriptive statistics including mean and standard devi-
ation are presented for all measures, and mean values did
not differ meaningfully form median. For the primary
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initial Wilcoxon rank-sum tests not subject to influence
by extreme outliers, followed by multivariable regression
analysis adjusting for BMI, duration of surgery, emergency
status, regional or general anesthesia, and type of proced-
ure. Unadjusted two-group tests were used to compare
periods on other variables. For categorical demographic
and outcome variables including gender, preoperative
characteristics, type of anesthesia used, and death within
30 days and 1 year, the Pearson chi-square tests were used
to determine P values, or the Pearson exact tests if counts
were sparse. For comparisons of continuous measures and
outcomes such as fluid volumes, length of stay, red blood
cells used, and percent change creatinine, Wilcoxon rank-
sum tests were used to determine P values. A P value
<0.05 was considered statistically significant. All analyses
were conducted on non-missing data; where data was in-
complete, it was assumed to be consistent with non-
missing data. SAS software version 9.3 (Cary, NC, USA)
was used for statistical analysis.
Results
Our database query for our defined sample initially
returned a set of 5,548 cases. We then excluded 95
whose fluid volumes were zero and 196 aged <18 yearsTable 1 Patient characteristics
2009 (n = 2,098)
Total N Mean or n SD or perce
Age (yrs) (mean, SD) 2,098 58.1 15.4








BMI (mean, SD) 1,884 29.6 7.3
CAD preop (n,%) 1,383 721 52.1
COPD preop (n,%) 1,383 83 6
CABG preop (n,%) 1,383 9 0.7
MI preop (n,%) 1,383 21 1.5
Preop valve dz (n,%) 1,383 48 3.5
Diabetes type I (n,%) 1,383 6 0.4
Diabetes type II (n,%) 1,383 224 16.2
Hypertension preop (n,%) 1,383 721 52.1
Preop creatinine (mean, SD) 1,370 1 0.6
yrs, years; Nat. Amer, Native American; BMI, body mass index; h/o, history of; CAD, c
valve dz, preoperative valve disease; CABG, coronary artery bypass graft; MI, myoca
standard deviation.old. We further excluded 206 who received <500 ml of
Voluven® alone and 163 receiving <500 ml of Hextend®
alone. The final overall analysis sample thus included
4,888 cases including 175 who received Plasmanate/al-
bumin alone.
From 1 June 2009 to 30 December 2009, 2,098 were in
the group in which Hextend® was the primary synthetic
colloid and from 1 June 2010 to 30 December 2010,
2,790 patients were in the group in which Voluven® was
available. An increase in surgical capacity accounts for
the increased number of patients in the 2010 period.
Otherwise, the patient demographics were similar in
terms of patient characteristics, preoperative comorbidi-
ties, and emergency surgery with inconsequential differ-
ences in proportions of ASA status and types of surgery
(Tables 1 and 2). Fewer patients in the 2010 group
(90.1% vs. 93%, P < 0.001) received general anesthesia
(Table 2). Intraoperative time and PACU time were simi-
lar between periods; however, in unadjusted outcomes,
mean volume of lactated Ringer’s given differed signifi-
cantly between periods; 2,252.9 ml in 2009 - Hextend®
group vs. 1,958.9 in 2010 - Voluven® group; P < 0.0001.
As expected, long-term follow-up also differed signifi-
cantly between periods (Table 2). In 2009, 1,906 subjects
received a mean of 767 ml (SD ± 301.8 ml) of Hextend®2010 (n = 2,790) P
valuentage Total N Mean or n SD or percentage
2,790 58 15.6 0.8910








2,639 29.5 7.3 0.9510
1,839 1,016 55.2 0.0792
1,839 116 6.3 0.7207
1,839 12 0.7 0.9951
1,839 29 1.6 0.8942
1,839 67 3.6 0.7938
1,839 11 0.6 0.6274
1,839 331 18 0.1799
1,839 1,016 55.2 0.0792
1,847 1.1 1.3 0.1725
oronary artery disease; COPD, chronic obstructive pulmonary disease; Preop
rdial infarction; DM, diabetes mellitus; preop, preoperative; SD,
Table 2 Procedural characteristics
2009 (n = 2,098) 2010 (n = 2,790) P value
Total N Mean or n SD or percentage Total N Mean or n SD or percentage
Emergency surgery (n,%) 1,878 149 7.9 2,677 226 8.4 0.5390
ASA class (n,%) 1,880 2,682 0.0045
1 48 2.6 59 2.2 0.4376
2 636 33.8 785 29.3 0.0011
3 1,074 57.1 1,612 60.1 0.0443
4 120 6.4 222 8.3 0.0168
5 2 0.1 4 0.1 1.0000
Procedure category 1,977 2,774 <0.0001
Misc. diagnostic (n,%) 4 0.2 10 0.4 0.4202
Obstetrical (n,%) 21 1.1 37 1.3 0.4007
Cardiovascular (n,%) 153 7.7 301 10.9 0.0003
Digestive (n,%) 398 20.1 530 19.1 0.3795
Ear (n,%) 32 1.6 73 2.6 0.0192
Endocrine (n,%) 17 0.9 33 1.2 0.2723
Eye (n,%) 3 0.2 4 0.1 1.0000
Female genital (n,%) 104 5.3 127 4.6 0.2811
Heme/lymphatic (n,%) 35 1.8 47 1.7 0.8427
Integumentary (n,%) 62 3.1 102 3.7 0.3141
Male genital (n,%) 104 5.3 104 3.7 0.0121
Musculoskeletal (n,%) 689 34.9 857 30.9 0.0041
Nervous system (n,%) 30 1.5 114 4.1 <0.0001
Nose, mouth, pharynx (n,%) 0 0 9 0.3 0.0129
Thoracic (n,%) 123 6.2 137 4.9 0.0553
Urinary (n,%) 139 7 199 7.2 0.8502
Other (n,%) 63 3.2 90 3.2 0.9115
General anes used (n,%) 1,977 1,848 93.5 2,774 2,499 90.1 <0.0001
Regional anes used (n,%) 1,977 647 32.7 2,774 930 33.5 0.5642
Surg. time (mins) (mean, SD) 1,505 240.8 128.6 2,399 242 131.8 0.8516
Rec’d any RBC, FFP, cryo (n,%) 1,977 440 22.3 2,774 578 20.8 0.2398
Days of follow-up (mean, SD) 1,976 1,081.6 323.6 2,774 776.7 211.6 <0.0001
Anes, anesthesia; SD, standard deviation; Misc, miscellaneous; Rec’d, received; RBC, red blood cell; Surg., surgical; Mins, minutes; FFP, fresh frozen plasma;
Cryo, cryoprecipitate.
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mean of 578.4 ml (SD ± 215 ml) in the PACU. The mean
amount of Hextend® given for the entire operative and
PACU period was 773.1 ml (SD ± 306.9 ml) compared to
933.7 ml (SD ± 518.4 ml) of Voluven® in 2010. Whereas,
2,650 subjects in the 2010 cohort received a mean of
905.8 ml (SD ± 495.5 ml) of Voluven® in the operative
period and 263 subjects received 645.3 ml (SD ±
260.7 ml) of Voluven® in the PACU. Considering the
volume of hetastarch, the mean volume of Hextend®
received per case in 2009 was significantly lower than
the mean volume of Voluven® received per case in 2010
(P < 0.001). The number of patients who received albumin,either alone or in combination with a perioperative
product, decreased from 220 to 31 patients from the
2009 - Hextend® to 2010 - Voluven® period, although
the mean volume of Plasmanate/albumin received per
case did not change significantly between periods.
In unadjusted outcomes, we did not find a difference
in blood product use in patients between periods; 22% of
patients in 2009 and 21% in 2010 received a blood prod-
uct which consisted of either a packed RBC, fresh frozen
plasma, or cryoprecipitate (Table 3). Patient outcomes
did not differ significantly between periods. Hospital
length of stay, change in creatinine from baseline repre-
sented as percent change from baseline creatinine, and
Table 3 Fluid volumes given
2009 (n = 2,098) 2010 (n = 2,790) P value
Total N Mean or n SD or percentage Total N Mean or n SD or percentage
Hextend intraop (ml) (mean, SD) 1,906 767 301.8
Hextend given in PACU (ml) (mean, SD) 51 578.4 215
Hextend entire case (ml) (mean, SD) 1,941 773.1 306.9
Voluven given intraop (ml) (mean, SD) 2,650 905.8 495.5
Voluven given in PACU (mean, SD) 263 645.3 260.7
Voluven entire case (ml) (mean, SD) 2,772 933.7 518.4
Plasmanate total (mean, SD) 220 467.4 346.9 31 460.5 267.8 0.5029
Lactated Ringer’s intraop (mean, SD) 1,861 2,232.7 1,324.7 2,591 1,943.7 1,098.5 <0.0001
Lactated Ringer’s PACU (mean, SD) 87 536.2 432.1 104 471.6 388.1 0.2710
Tot lac. Ringer’s (ml) (mean, SD) 1,865 2,252.9 1,332.5 2,596 1,958.9 1,106.2 <0.0001
Normal saline intraop (mean, SD) 335 932.7 766.9 488 940 739.4 0.7984
Normal saline PACU (mean, SD) 12 175.3 158.1 45 194 205.7 0.8882
Tot N saline (ml) (Mean, SD) 344 914.5 767.4 524 892.1 744.5 0.5633
RBC’s intraop (mean, SD) 388 1,166.7 1,406.3 505 1,058.3 1,084.5 0.4291
RBC’s PACU (mean, SD) 72 597.9 313.6 82 557.6 227.9 0.8751
RBC’s total (mean, SD) 433 1,144.9 1,342.3 564 1,028.7 1,039.8 0.1790
FFP intraop (mean, SD) 123 1,069.5 1,095.3 171 947.7 938.8 0.1482
FFP PACU (mean, SD) 10 407.2 150.6 8 485.9 160.6 0.4205
Tot FFP (ml) (mean, SD) 131 1,035.3 1,071.2 177 937.5 926.6 0.2260
Cryoprecipitate intraop (mean, SD) 10 161.6 68.5 30 149.5 94.3 0.3885
Cryoprecipitate total (mean, SD) 10 161.6 68.5 31 147.9 93.1 0.3502
Intraop, intra-operative; ml, milliliters; PACU, post-anesthesia care units; Tot, Total; ml, milliliters; Lac, lactated Ringer’s; N, normal; RBC, red blood cell; FFP, fresh
frozen plasma.
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were similar between periods (Tables 3 and 4). Similarly,
postoperative mortality at 30-day and 1-year mortality
was also similar (Table 4). However, surprising overall
total fluid costs in the operating room and the PACU in
2013 dollars were significantly greater in the group in
2010 - Voluven® period compared to the 2009 - Hextend®
period ($122.1 compared to $68.03; P <0.001) (Table 5).
After adjusting for age, BMI, length of surgery, and type of
anesthetic, Voluven® was still associated with increased
fluid costs. The R2 for this multivariable model was 0.379,
and the difference between periods remained significant
with P < 0.001. Age, COPD, history of hypertension, and
preoperative creatinine were also tested but dropped as
non-significant effects. Results of the confirmatory ana-
lyses comparing all pre- vs. post-conversion cases were
very consistent with the primary results.
Discussion
In this study, we had expected that the switch from
Hextend® to Voluven® would be associated with overall
decreased fluid acquisition costs due to lower utilization of
albumin, an improved profile on intravascular coagulationand less need for other intravascular volume expanders as
well as blood products. However, although patient demo-
graphics and outcomes were similar between trial periods,
in both unadjusted and adjusted analyses, overall costs as-
sociated with the 2010 - Voluven® period were greater
than the 2009 - Hextend® period. The lower cost of Plas-
manate/albumin was more than offset by the considerably
higher unit cost of Voluven® coupled with a higher volume
of Voluven® given per case.
As many hospitals in the US are receiving bundled
payments for surgical procedures, the overall hospital
costs associated with surgery is becoming more import-
ant to define [15-17]. This is the first study to present
the effects of a switch from Hextend® to Voluven® on
fluid costs to the hospital during the perioperative
period. Many surgical groups are using enhanced recov-
ery after surgery (ERAS) protocols in colorectal and
other surgeries which recommend giving a semisynthetic
colloid as a plasma volume expander in the intraopera-
tive goal-directed fluid therapy algorithm in an effort to
reduce total crystalloid use [18]. The use of colloid in
combination with crystalloid has been shown to decrease
postoperative bowel dysfunction, including incidence of
Table 4 Health-care outcomes
2009 (n = 2,098) 2010 (n = 2,790) P value
Total N Mean or n SD or percentage Total N Mean or n SD or percentage
Any PACU time (n,%) 1,977 1,498 75.8 2,774 2,053 74 0.1681
PACU time (hrs, incl. 0) (mean, SD) 1,977 3.2 3.3 2,774 3.2 3.3 0.0848
PACU hrs if > 0 (mean, SD) 1,498 4.3 3.2 2,053 4.3 3.2 0.2991
Any ICU stay (n,%) 1,971 339 17.2 2,774 629 22.7 <0.0001
ICU days 1,971 2,774 <0.0001
None (n,%) 1,632 83 2,145 77 <0.0001
1 day (n,%) 137 7 247 9 0.0150
2 to 3 days (n,%) 114 6 189 7 0.1530
4+ days (n,%) 88 4 193 7 0.0003
Total ICU days (incl. 0) (mean, SD) 1,971 0.9 4.8 2,774 1 4.2 <0.0001
ICU days if > 0 (mean, SD) 339 5.2 10.7 629 4.5 7.8 0.3676
Highest postop creatinine (mean, SD) 1,901 1.2 1 2,634 1.4 1.5 0.0884
Creatinine pre-post percentage change (mean, SD) 1,310 24.1 69 1,735 24.1 63.6 0.4533
LOS (days) (mean, SD) 1,977 7.3 9.2 2,774 7.3 9.6 0.8711
Death - 30 days (n,%) 1,977 32 1.6 2,774 49 1.8 0.6981
Death - 1 year (n,%) 1,977 164 8.3 2,774 238 8.6 0.7286
PACU, post-anesthesia care units; postop, postoperative; hrs, hours; SD, standard deviation; ICU, intensive care unit; creatinine pre-post, creatinine pre-surgery
post-surgery; LOS, length of stay.
Bartz et al. Perioperative Medicine  (2015) 4:2 Page 6 of 7postoperative nausea and vomiting, use of rescue anti-
emetic, as well as pain and edema symptoms in major
surgery [2]. Although our study showed an increased
direct acquisition cost to the hospital in 2010 - Voluven®
over 2009 - Hextend® period. A recent study at this
institution suggests that goal-directed fluid therapy in
which Voluven® was used as part of an ERAS algo-
rithm resulted in a 1-L decrease in crystalloid use
overall and earlier return to bowel function in pa-
tients undergoing bowel surgery as well as a 2-day re-
duction in hospital length of stay [19]. Whether the
use of a plasma expander or other parts of the ERAS
bundle contributed to this decreased length of stay
needs further study. We did not target a specificTable 5 Direct fluid acquisition costs in the Hextend® and Vo
2009 (n = 2,098)
Total N Mean SD
Hextend units cost 2,098 $55.13 $2
Voluven units cost 2,098 $0.00 $0
Plasmanate units cost 2,098 $8.07 $2
LR units cost 1,977 $4.84 $2
NS units cost 1,977 $0.60 $1
Colloids (Hex/Vol + Plas) cost 2,098 $63.20 $3
All fluids units cost (observed) 1,977 $68.03 $3
All fluids units cost (imputed) 2,098 $68.65 $3
Cost ($) statistics include all cases (none given = $0). ml, milliliters; LR, lactated Ringpopulation in our study, and future studies should
specifically focus on this area of investigation and
question which part of the ERAS bundle leads to the
most beneficial patient outcomes.
Several limitations to the current study need consider-
ation. This is a single center study, and hence, the re-
sults may not be generalizable to other institutions or
other countries given differences in fluid acquisition
costs and availability depending on regulatory agencies.
Also, given the retrospective nature of this study, un-
accounted confounders may exist which may have skewed
our results. However, because baseline demographics are
similar as the types of surgeries, this is less likely to be a
major issue.luven® groups
2010 (n = 2,790) P value
Total N Mean SD
7.80 2,790 $0.00 $0.00 <0.0001
.00 2,790 $116.01 $65.05
9.85 2,790 $0.85 $9.21 <0.0001
.93 2,774 $4.31 $2.52 <0.0001
.49 2,774 $0.64 $1.53 0.196
3.53 2,790 $116.87 $64.80 <0.0001
3.22 2,774 $122.10 $65.85 <0.0001
4.68 2,790 $121.82 $65.82
er’s; NS, normal saline; SD, standard deviation.
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In summary, after converting from Hextend® to Voluven®
in a large tertiary medical institution, no differences were
seen in short- and long-term mortality, renal outcome,
blood and blood product utilization, ICU, or hospital
length of stay. Although the number of cases receiving al-
bumin decreased, total intraoperative and PACU intravas-
cular volume fluid acquisition costs were greater.
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